MEK4 (MAP2K4) Human shRNA Lentiviral Particle (Locus ID 6416)

CAT#: TL320527V

MAP2K4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.


Biosafety Sheet

USD 1,731.00

3 Weeks*

Size
    • 500 ul each

Product Images

Frequently bought together (2)
Control Lenti particles, Scrambled shRNA, Expressing GFP and Puro, >1x10^7 TU/ml, 0.5 ml
    • 1 x 10^7 TU/ml, 500 ul

USD 365.00


One-Wash Lentivirus Titer Kit, HIV-1 p24 ELISA
    • 96 reactions

USD 550.00

Other products for "MAP2K4"

Specifications

Product Data
Locus ID 6416
Synonyms JNKK; JNKK1; MAPKK4; MEK4; MKK4; PRKMK4; SAPKK-1; SAPKK1; SEK1; SERK1; SKK1
Vector pGFP-C-shLenti
Format Lentiviral particles
RefSeq NM_001281435, NM_003010, NM_003010.1, NM_003010.2, NM_003010.3, NM_001281435.1, BC036032, BC036032.1, BC050386, BC060764, NM_001281435.2, NM_003010.4
UniProt ID P45985
Summary This gene encodes a member of the mitogen-activated protein kinase (MAPK) family. Members of this family act as an integration point for multiple biochemical signals and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation, and development. They form a three-tiered signaling module composed of MAPKKKs, MAPKKs, and MAPKs. This protein is phosphorylated at serine and threonine residues by MAPKKKs and subsequently phosphorylates downstream MAPK targets at threonine and tyrosine residues. A similar protein in mouse has been reported to play a role in liver organogenesis. A pseudogene of this gene is located on the long arm of chromosome X. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
shRNA Design These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.